Jan J. Jobsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jan J. Jobsen has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Job van der Palen
Department of Epidemiology Medisch Spectrum Twente Enschede The Netherlands
7 shared publications - Carien L. Creutzberg
Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands
3 shared publications Francisca Ong
A Department of Radiation Oncology , Medisch Spectrum Twente , Enschede , The Netherlands
3 shared publicationsHenk Struikmans
E Department of Radiation Oncology , Leiden University Medical Centre , Leiden , The Netherlands , and
3 shared publications- Henk Struikmans
Department of Radiation Oncology, Leiden University Medical Centre, Leiden, The Netherlands
3 shared publications J.W.M. Mens
3 shared publications
Latest Publications
- 23 September 2015
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 55 (4) , 449-454
Long-term effects of first degree family history of breast cancer in young women: Recurrences and bilateral breast cancer
Background. The aim of this study is to analyze the impact of first degree relative (FDR) of young breast cancer patients. Methods. Data were used from our prospective population-based cohort study which started in 1983. The family history (FH) was registered with regard to FDR: the presence or absence of invasive breast cancer in none vs. one or more FDRs at any age. Results. A total of 1109 women, ≤50 years with 1128 breast conserving treatments was seen. The incidence of FDR was 17.0% for one FDR and 3.2% ≥2 FDR. The three groups, none, 1 or ≥2 FDR, were comparable. The local failure rate is comparable for all three groups. Women with a positive FH and metachronous bilateral breast cancer (MBBC) showed a lower local failure (HR 0.2; 95% CI 0.05–0.8). A positive FH was an independent predictor for a better disease-specific survival (HR 0.6; 95% CI 0.4–0.9). Conclusion. A positive FH, based on FDR implies a better prognosis in relation to survival for young women treated with BCT. In contrast to no FH for FDR, MBBC in women with a positive FH was not associated with an increased risk of local recurrence.
- 23 September 2015
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 55 (4) , 449-454
Long-term effects of first degree family history of breast cancer in young women: Recurrences and bilateral breast cancer
Background. The aim of this study is to analyze the impact of first degree relative (FDR) of young breast cancer patients. Methods. Data were used from our prospective population-based cohort study which started in 1983. The family history (FH) was registered with regard to FDR: the presence or absence of invasive breast cancer in none vs. one or more FDRs at any age. Results. A total of 1109 women, ≤50 years with 1128 breast conserving treatments was seen. The incidence of FDR was 17.0% for one FDR and 3.2% ≥2 FDR. The three groups, none, 1 or ≥2 FDR, were comparable. The local failure rate is comparable for all three groups. Women with a positive FH and metachronous bilateral breast cancer (MBBC) showed a lower local failure (HR 0.2; 95% CI 0.05–0.8). A positive FH was an independent predictor for a better disease-specific survival (HR 0.6; 95% CI 0.4–0.9). Conclusion. A positive FH, based on FDR implies a better prognosis in relation to survival for young women treated with BCT. In contrast to no FH for FDR, MBBC in women with a positive FH was not associated with an increased risk of local recurrence.
- 1 August 2015
- Published by Elsevier in The Breast
- Vol. 24 (4) , 468-475
Factors influencing time between surgery and radiotherapy: A population based study of breast cancer patients
- 1 August 2015
- Published by Elsevier in The Breast
- Vol. 24 (4) , 468-475
Factors influencing time between surgery and radiotherapy: A population based study of breast cancer patients
- Open Access
- 1 April 2015
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 115, S213
PD-0436: Long-term bowel and bladder symptoms after pelvic radiotherapy or vaginal brachytherapy in the PORTEC-2 trial
- 1 April 2015
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 115, S213
Open AccessPD-0436: Long-term bowel and bladder symptoms after pelvic radiotherapy or vaginal brachytherapy in the PORTEC-2 trial
- 1 August 2014
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 89 (5) , 1006-1014
Pattern of Ipsilateral Breast Tumor Recurrence After Breast-Conserving Therapy
- 1 August 2014
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 89 (5) , 1006-1014
Pattern of Ipsilateral Breast Tumor Recurrence After Breast-Conserving Therapy
- Open Access
- 5 February 2013
- Published by Springer Nature in British Journal of Cancer
- Vol. 108 (4) , 820-825
Timing of radiotherapy in breast-conserving therapy: a large prospective cohort study of node-negative breast cancer patients without adjuvant systemic therapy
Background: Methods: Results: Conclusion:
- 5 February 2013
- Published by Springer Nature in British Journal of Cancer
- Vol. 108 (4) , 820-825
Open AccessTiming of radiotherapy in breast-conserving therapy: a large prospective cohort study of node-negative breast cancer patients without adjuvant systemic therapy
Background: Methods: Results: Conclusion:
- 1 May 2012
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 103, S119-S120
PD-0302 IMPROVED RISK ASSESSMENT OF ENDOMETRIAL CANCER PATIENTS BY ANALYSIS OF MSI, PI3K-AKT, WNT AND P53 PATHWAY
- 1 May 2012
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 103, S119-S120
PD-0302 IMPROVED RISK ASSESSMENT OF ENDOMETRIAL CANCER PATIENTS BY ANALYSIS OF MSI, PI3K-AKT, WNT AND P53 PATHWAY
- 1 April 2012
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 82 (5) , e811-e817
Sequence of Radiotherapy and Chemotherapy in Breast Cancer After Breast-Conserving Surgery
- 1 April 2012
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 82 (5) , e811-e817
Sequence of Radiotherapy and Chemotherapy in Breast Cancer After Breast-Conserving Surgery
- Open Access
- 4 May 2011
- Published by Hindawi Limited in Obstetrics and Gynecology International
- Vol. 2011, 1-7
Outcome of Endometrial Cancer Stage IIIA with Adnexa or Serosal Involvement Only
Objective. The aim of this study is to look at possible differences in outcome between serosa and adnexal involvement stage IIIA endometrial carcinoma. Methods. 67 patients with stage IIIA endometrial carcinoma were included, 46 with adnexal involvement and 21 with serosa. A central histopathological review was performed. Results. The 7-year locoregional failure rate was (LRFR) 2.2% for adnexal involvement and 16.0% for involvement of the serosa (𝑃=.0522). The 7-year distant metastasis-free survival was 72.7% for adnexal involvement and 58.7% for serosa (𝑃=.3994). The 7-year disease-specific survival (DSS) was 71.8% for patients with adnexal involvement and 75.4% for patients with serosa. Conclusion. Endometrial carcinoma stage IIIA with involvement of the adnexa or serosa showed to have a comparable disease-specific survival. Locoregional control was worse for serosa involvement compared to adnexa.
- 4 May 2011
- Published by Hindawi Limited in Obstetrics and Gynecology International
- Vol. 2011, 1-7
Open AccessOutcome of Endometrial Cancer Stage IIIA with Adnexa or Serosal Involvement Only
Objective. The aim of this study is to look at possible differences in outcome between serosa and adnexal involvement stage IIIA endometrial carcinoma. Methods. 67 patients with stage IIIA endometrial carcinoma were included, 46 with adnexal involvement and 21 with serosa. A central histopathological review was performed. Results. The 7-year locoregional failure rate was (LRFR) 2.2% for adnexal involvement and 16.0% for involvement of the serosa (𝑃=.0522). The 7-year distant metastasis-free survival was 72.7% for adnexal involvement and 58.7% for serosa (𝑃=.3994). The 7-year disease-specific survival (DSS) was 71.8% for patients with adnexal involvement and 75.4% for patients with serosa. Conclusion. Endometrial carcinoma stage IIIA with involvement of the adnexa or serosa showed to have a comparable disease-specific survival. Locoregional control was worse for serosa involvement compared to adnexa.
- 1 April 2010
- Published by Elsevier in Gynecologic Oncology
- Vol. 117 (1) , 32-36
The number of metastatic sites for stage IIIA endometrial carcinoma, endometrioid cell type, is a strong negative prognostic factor
- 1 April 2010
- Published by Elsevier in Gynecologic Oncology
- Vol. 117 (1) , 32-36
The number of metastatic sites for stage IIIA endometrial carcinoma, endometrioid cell type, is a strong negative prognostic factor
- 28 February 2010
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 36 (2) , 176-181
The impact of margin status in breast-conserving therapy for lobular carcinoma is age related
- 28 February 2010
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 36 (2) , 176-181
The impact of margin status in breast-conserving therapy for lobular carcinoma is age related